Overview
Status
Active
Registry date
2019-09-25
Share capital
5,000.00 PLN
Registered address
ul. Wronia 10, 00-840 Warszawa, Poland
Electronic delivery address
AE:PL-77801-41296-RRUWH-33
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 213 days for 2021).
- 202530/06/2026
- 202409/06/2025
- 202316/07/2024
- 202203/07/2023
- 202113/02/2023
- 202001/07/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.48mMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD 117.04kMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 1.34mMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 549.37kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Michael Joseph Ryan – Management Board Member
Manner of representation
Each member of the management board independently is authorised to submit declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Eversana Ireland Limited | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-10-17.
No bank accounts reported to the VAT Taxpayer Register.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| Proper Medical Writingsp. z o.o. | $464,661.64 | propermedicalwriting.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-08 | Address change (Ul. Towarowa 28, 00-839, Warszawa → Ul. Wronia 10, 00-840, Warszawa) | |
| 2022-09-20 | Address change (Ul. Inflancka 4, 00-189, Warszawa → Ul. Towarowa 28, 00-839, Warszawa) | |
| 2022-01-31 | Name change (W017 → Eversana Poland) | |
| 2022-01-31 | PKD change (Removed: 8 codes; Added: 2 codes) | |
| 2020-01-31 | Address change (Ul. Miła 2, 00-180, Warszawa → Ul. Inflancka 4, 00-189, Warszawa) |
FAQ
The main business activity of Eversana Poland focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on September 25, 2019.
The headquarters is located at: ul. Wronia 10, 00-840 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $1,202,334 in 2024, which is an increase of 39.6% compared to 2023.
Yes, the company recorded a net profit of $95,715 in 2024, meaning the company increased its profit by 44.6%.
The largest operating cost category falls under employee remuneration. This category amounted to $799,985 in 2024, representing 73% of all operating expenses.
Last updated: 2026-10-07